餐后高血糖和心血管危險因素(存儲版)
【正文】 y 12 11 10 9 8 7 6 5 0 12 24 36 48 60 72 Months HbA1c (%) FPG = fasting plasma glucose。45(Suppl. 2):A104. Hypertension* Myocardial infarction Any cardio vascular event p= p= p= 34% 91% 49% Reducing postprandial hyperglycaemia decreases the risk of diabetes and CVD STOP NIDDM Acarbose treatment resulted in a ? Relative risk reduction of 25% for the development of diabetes (p=)1 ? Relative risk reduction of 36% using two consecutive OGTTs (p=)1 ? 30% increase in the incidence of normal glucose tolerance (p)2 ? Statistically significant reduction in the risk of – hypertension – myocardial infarction – any cardiovascular event CVD: cardiovascular disease, OGTT: oral glucose tolerance test 1. Chiasson JL, et al. Diabetologia 2022。359:2072–7. p 25% 21% 31% 23% 29% 24% 30% 0 Favours acarbose Overall Age (years) 55 55 Sex Male Female BMI (kg/m2) 30 30 Favours placebo Reduction in incidence Acarbose increases the reversion of IGT to NGT NGT IGT Diabetes At baseline Acarbose group (%) Placebo group (%) 32 42 28 25 35 31 At end of treatment 100% * * *No postrandomisation data IGT: impaired glucose tolerance, NGT: normal glucose tolerance Chiasson JL, et al. Lancet 2022。110:637–41. Macro vascular disease Insulin sensitivity Insulin secretion Plasma glucose Micro vascular disease Impaired glucose tolerance Hyperglycemia Diagnosing glucose intolerance – criteria reflect a need for early intervention *Determined post 75g glucose load 2hPG: 2hour postchallenge plasma glucose, FPG: fasting plasma glucose, IFG: impaired fasting glucose, IGT: impaired glucose tolerance World Health Organization, 1999. Diagnosis Venous plasma glucose concentration (mmol/L) Diabetes FPG or 2hPG* IGT FPG (if measured) and
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1